{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:33:34Z","timestamp":1758710014002},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>An effective antitumor immune response in patients with lymphoma would eradicate the malignant B cells and cure the patient of the disease. This, however, does not occur, and a suboptimal antitumor response results in persistence and subsequent progression of the patient\u2019s disease. The goals of immunotherapy are therefore to restore an effective antitumor immune response by promoting immune recognition, optimizing immune activation, and supporting persistence of the immune response resulting in subsequent immunological memory. Multiple mechanisms, however, are present within the tumor microenvironment that account for an inadequate immune response. These include loss of major histocompatibility complex expression on tumor cells and subsequent inadequate antigen presentation, increased expression of immunosuppressive ligands on malignant cells, populations of immune cells with suppressive function present in the tumor, and cytokines secreted by the malignant cell or other cells in the microenvironment that promote immune exhaustion or suppress the immune response. Successful immunotherapeutic strategies are specifically addressing these issues by promoting antigen presentation, improving recognition of the malignant cell, directly activating T cells and natural killer cells, and blocking immune checkpoint signaling that would suppress the immune response. Many of these approaches have proven highly successful in patients with various subtypes of lymphoma and are now being incorporated into standard clinical practice.<\/jats:p>","DOI":"10.1182\/hematology.2020002537","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T04:44:35Z","timestamp":1607143475000},"page":"585-589","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Fundamentals of immunology for understanding immunotherapy for lymphoma"],"prefix":"10.1182","volume":"2020","author":[{"given":"Stephen M.","family":"Ansell","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"suppl 3","key":"2020121621272920400_B1","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1016\/j.vaccine.2010.07.022","article-title":"Key concepts in immunology","volume":"28","author":"Moser","year":"2010","journal-title":"Vaccine"},{"key":"2020121621272920400_B2","doi-asserted-by":"crossref","first-page":"1467538","DOI":"10.1155\/2018\/1467538","article-title":"The regulation of inflammation by innate and adaptive lymphocytes","volume":"2018","author":"Cronkite","year":"2018","journal-title":"J Immunol Res"},{"issue":"2","key":"2020121621272920400_B3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tibs.2017.11.008","article-title":"TCR signaling: mechanisms of initiation and propagation","volume":"43","author":"Courtney","year":"2018","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"2020121621272920400_B4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2020121621272920400_B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/TP.0000000000000169","article-title":"Co-inhibitory pathways and their importance in immune regulation","volume":"98","author":"Murakami","year":"2014","journal-title":"Transplantation"},{"issue":"5","key":"2020121621272920400_B6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"2020121621272920400_B7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"2020121621272920400_B8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2019000847","article-title":"The immune landscape and response to immune checkpoint blockade therapy in lymphoma","volume":"135","author":"Kline","year":"2020","journal-title":"Blood"},{"key":"2020121621272920400_B9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/asheducation-2017.1.610","article-title":"Role of the microenvironment across histological subtypes of NHL","volume":"2017","author":"Tarte","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2020121621272920400_B10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2020121621272920400_B11","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.celrep.2019.01.085","article-title":"Mass cytometry analysis reveals that specific intratumoral CD4+ T cell subsets correlate with patient survival in follicular lymphoma","volume":"26","author":"Yang","year":"2019","journal-title":"Cell Rep"},{"issue":"11","key":"2020121621272920400_B12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced \u03b22M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"2020121621272920400_B13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020121621272920400_B14","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/blood-2003-07-2365","article-title":"Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project","volume":"103","author":"Rimsza","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2020121621272920400_B15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2005-11-4742","article-title":"Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival","volume":"108","author":"Roberts","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2020121621272920400_B16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/10428199109064876","article-title":"Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class II (HLA-DR, DP, DQ) and class I (HLA-A, B, C) phenotype","volume":"6","author":"Rybski","year":"1991","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2020121621272920400_B17","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1158\/1078-0432.CCR-05-2617","article-title":"Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma","volume":"12","author":"Booman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2020121621272920400_B18","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7338","key":"2020121621272920400_B19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"issue":"23","key":"2020121621272920400_B20","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"2020121621272920400_B21","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2020121621272920400_B22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/2326-6066.CIR-18-0351","article-title":"TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma","volume":"7","author":"Josefsson","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2020121621272920400_B23","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J Clin Invest"},{"issue":"7","key":"2020121621272920400_B24","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/bloodadvances.2019001390","article-title":"LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma","volume":"4","author":"Keane","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2020121621272920400_B25","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov"},{"issue":"7","key":"2020121621272920400_B26","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1182\/blood-2007-03-082578","article-title":"CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"issue":"14","key":"2020121621272920400_B27","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2009-05-220111","article-title":"Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2020121621272920400_B28","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2020121621272920400_B29","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","article-title":"T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells","volume":"128","author":"Azzaoui","year":"2016","journal-title":"Blood"},{"issue":"7","key":"2020121621272920400_B30","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1038\/bcj.2015.56","article-title":"IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low\/-) monocytes in B-cell non-Hodgkin lymphoma","volume":"5","author":"Xiu","year":"2015","journal-title":"Blood Cancer J"},{"issue":"9","key":"2020121621272920400_B31","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/leu.2014.84","article-title":"TGF-\u03b2 upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin\u2019s lymphoma","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"2020121621272920400_B32","article-title":"A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies [published online ahead of print 29 June 2020]","author":"Armand","journal-title":"Leukemia"},{"issue":"9","key":"2020121621272920400_B33","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1182\/bloodadvances.2019001079","article-title":"Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies","volume":"4","author":"Ansell","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2020121621272920400_B34","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/1078-0432.CCR-19-2973","article-title":"First-in-human study of utomilumab, a 4-1BB\/CD137 agonist, in combination with rituximab in patients with follicular and other CD20+ non-Hodgkin lymphomas","volume":"26","author":"Gopal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2020121621272920400_B35","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"26","key":"2020121621272920400_B36","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2020121621272920400_B37","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.clml.2019.09.598","article-title":"Recent advances in CAR-T cell therapy for non-Hodgkin lymphoma","volume":"19","author":"Kallam","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2020121621272920400_B38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.blre.2008.09.001","article-title":"Vaccines for lymphomas: idiotype vaccines and beyond","volume":"23","author":"Houot","year":"2009","journal-title":"Blood Rev"},{"issue":"10","key":"2020121621272920400_B39","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"issue":"18","key":"2020121621272920400_B40","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/585\/1795140\/hem2020002537c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/585\/1795140\/hem2020002537c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:20:42Z","timestamp":1608315642000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/585\/474353\/Fundamentals-of-immunology-for-understanding"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020002537","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}